iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium

iCAN-PREVENT：MD 安德森国际癌症预防临床试验联盟

基本信息

批准号：
10470838
负责人：
POWEL H BROWN
金额：
$ 91.13万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-15 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10470838
关键词：
Advanced Malignant Neoplasm Antigens Applications Grants Aromatase Inhibitors Aspirin Bioinformatics Biological Markers Bladder Breast Breast Cancer Prevention Budesonide Cancer Prevention Intervention Cancer Prevention Trial Cause of Death Cells Cessation of life Clinical Clinical Chemoprevention Clinical Research Clinical Trials Colon Carcinoma Colorectal Colorectal Neoplasms Conduct Clinical Trials Coupled Critical Pathways DNA Death Rate Development Disease Dose Dropout Drug Formulations Early Diagnosis Eligibility Determination Endometrial Neoplasms Enrollment Epigallocatechin Gallate Esophagus Exemestane Facebook Future Goals Green tea Head and Neck Cancer Hematology Hereditary Neoplastic Syndromes Hereditary Nonpolyposis Colorectal Neoplasms High-Risk Cancer Immune Immune response Immune system Immunomodulators Incidence Individual Infiltration Inhalation International Intervention Lesion Lung Malignant Neoplasms Malignant neoplasm of liver Malignant neoplasm of lung Malignant neoplasm of urinary bladder Mammary Gland Parenchyma Methods Modification Molecular Molecular Analysis Naproxen Non-Steroidal Anti-Inflammatory Agents Participant Pathologist Pathway interactions Patients Peptides Pharmaceutical Preparations Pharmacotherapy Phase Phase II/III Trial Prevention Prevention strategy Prevention trial Preventive Preventive therapy Preventive vaccine Prostate Public Health Recording of previous events Research Personnel Risk Role SDZ RAD Safety Sampling Schedule Series Signal Pathway Signal Transduction Social Network Steroids Stomach Neoplasms Testing Twitter United States Update Vaccine Clinical Trial Vaccine Therapy Vaccines Visit Woman Zileuton base cancer prevention disorder risk drug development drug efficacy eHealth early phase clinical trial early phase trial eligible participant experience high risk high risk population improved inhibitor mTOR Inhibitor mTOR inhibition mortality neoantigens news novel novel strategies novel therapeutics phase 3 testing phase I trial phase II trial premalignant prevent prevention clinical trial preventive intervention programs recruit response safety testing screening side effect social media tissue biomarkers translational scientist triple-negative invasive breast carcinoma tumor tumorigenesis

项目摘要

Abstract Cancer-related death is the second most common cause of death in the US, and the most promising strategy to reduce cancer-related deaths and cancer incidence is through cancer prevention. Previous clinical trials have demonstrated the feasibility of preventing cancer using vaccines or cancer preventive drugs. However, the use of these agents is limited due to their side effects. Clearly, safer and more effective cancer prevention interventions that are acceptable to healthy individuals are urgently needed. Thus, the overarching goal of this application is to bring a team of basic, translational, and clinical researchers together to identify novel strategies to prevent cancer, test them in cancer prevention clinical trials, and ultimately bring safe, efficacious, and acceptable preventive therapies to general use in individuals at high- risk of this disease. To achieve this goal, we formed an international consortium (the iCAN- PREVENT consortium) comprised of cancer prevention experts, clinical trialists, molecular biologists, translational researchers, pathologists, statisticians, and bio-informatics experts, to develop and conduct early phase cancer prevention trials. Our clinical research team has vast experience in conducting both early and late phase clinical trials, and has conducted 18 Phase I and II cancer prevention clinical trials through our previous chemoprevention clinical trial consortia. Here, we propose two aims to test the hypothesis that we can conduct trials of drug and vaccine therapies and demonstrate that these preventive therapies will safely modulate critical tumor promoting pathways. Results from these early phase clinical trials will support the advancement of these interventions to Phase III testing, and ultimately support the FDA-approval of these interventions for cancer prevention. We will 1) conduct 5 to 10 early phase clinical trials testing the safety and activity of a series of promising cancer prevention drugs, vaccines, and immune modulating interventions in individuals at high-risk of cancer, and 2) develop and implement novel methods to enhance recruitment and retention of patients in prevention trials using social media, electronic news-blasts, and mobile messaging. To demonstrate our ability to develop novel cancer prevention trials, we provide two sample trials: a Phase I trial of a novel DNA-based vaccine encoding novel frameshift antigens that develop in individuals with Lynch Syndrome, and a Phase II trial testing the ability of the mTOR inhibitor everolimus to alter breast tissue biomarkers in individuals with prior triple-negative breast cancer. The results of these early phase trials will advance cancer prevention drug development, and will ultimately help reduce cancer incidence and mortality through prevention.

抽象的与癌症相关的死亡是美国第二常见的死亡原因，也是最常见的死亡原因，也是最常见的死亡减少癌症相关死亡和癌症发病率的有希望的策略是通过癌症预防。以前的临床试验已经证明了预防使用癌症的可行性疫苗或癌症预防药物。但是，这些代理的使用受到限制副作用。显然，更安全，更有效的癌症预防干预措施迫切需要健康的个体可以接受。因此，这个总体目标应用是将一组基本，转化和临床研究人员聚集在一起以确定预防癌症，在预防癌症临床试验中测试癌症的新型策略，并最终将安全，有效且可接受的预防疗法带入高处的个体中这种疾病的风险。为了实现这一目标，我们成立了一个国际财团（ICAN- 预防财团）由癌症预防专家，临床试验者，分子组成生物学家，转化研究人员，病理学家，统计学家和生物信息学专家，开发和进行早期癌症预防试验。我们的临床研究团队拥有广阔的进行早期和晚期临床试验的经验，并进行了18阶段I 和II癌症预防临床试验通过我们以前的化学预防临床试验财团。在这里，我们提出了两个目标，以检验我们可以进行药物试验的假设和疫苗疗法，并证明这些预防疗法将安全调节关键肿瘤促进途径。这些早期临床试验的结果将支持这些干预措施的进步对III期测试，并最终支持FDA批准这些预防癌症的干预措施。我们将1）进行5至10个早期临床试验测试一系列有前途的预防药物，疫苗和活动的安全性和活动免疫调节癌症患者的干预措施，以及2）发展和实施新的方法来增强预防试验中患者的招募和保留使用社交媒体，电子新闻爆炸和移动消息传递。展示我们的能力为了开发新型的癌症预防试验，我们提供了两个样本试验：一项新型的I期试验基于DNA的疫苗编码在患有lynch的个体综合征和II期试验测试MTOR抑制剂Everolimus改变乳房的能力先前三阴性乳腺癌个体的组织生物标志物。这些结果早期试验将推动预防癌症的药物开发，并最终有助于通过预防降低癌症的发病率和死亡率。